XPAR
GNFT
Market cap512mUSD
Oct 09, Last price
8.28EUR
1D
-0.60%
1Q
-39.74%
Jan 2017
-60.59%
IPO
-34.14%
Name
Genfit SA
Chart & performance
P/E
275.16
P/S
6.19
EPS
0.03
Div yield, %
—
Shrs. gr., 5y
6.31%
Rev. gr., 5y
16.79%
Revenues
67m
+134.56%
Net income
2m
P
CFO
16m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genfit S.A. functions as a late-stage biopharmaceutical enterprise, primarily dedicated to the identification and advancement of novel therapeutic drugs and diagnostic technologies for metabolic and liver-related conditions. A prominent candidate in its pipeline is Elafibranor, currently in Phase III clinical trials for treating primary biliary cholangitis. The company is also developing NIS4, a diagnostic platform aimed at identifying nonalcoholic steatohepatitis (NASH) and fibrosis. Its diverse portfolio further includes VS-01, designed for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is undergoing Phase 1b/2a trials for cholangiocarcinoma (CCA); and a combination of VS-01-ACLF with Nitazoxanide (NTZ), in Phase 1 for acute-on-chronic liver failure. Additionally, Genfit is researching VS-02-HE in preclinical stages to reduce hyperammonemia and stabilize blood ammonia, alongside SRT-015, an ASK1 inhibitor engineered to suppress cellular apoptosis, inflammation, and fibrosis. Genfit has established strategic collaborations, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. It also partnered with Genoscience Pharma to jointly develop and market the experimental treatment GNS561 for CCA. The company was founded in 1999 and is headquartered in Loos, France.
Key people
Jean-Francois Mouney
Chairman of the Board · since 2019
Pascal Prigent
Chief Executive Officer · since 2019
Thomas Baetz
Chief Financial Officer · since 2021
Pascal Caisey
Chief Operating Officer · since 2022
John Brozek
Executive Vice President - Data and Information Technology · since 2022
Emilie Desodt
Executive Vice President of Human Resources · since 2022
Tom Huijbers
Executive Vice President - Regulatory · since 2023
Stefanie Magner
Executive Vice President - International Legal Affairs, Chief Compliance Officer · since 2021
Sakina Sayah-Jeanne
Executive Vice President - Research & Translational Science · since 2023
Meriam Kabbaj
Chief Technology Officer · since 2022
Dean Hum
Chief Scientific Officer · since 2022
Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG · since 2022
Laurent Lannoo
Corporate Secretary, Director of Legal Affairs · since 2012
Florence Sejourne
Director, Representative of Biotech Avenir · since 2017
Director, Representative of Ipsen · since 2023
Eric Baclet
Independent Vice Chairman of the Board · since 2024
Katherine Kalin
Independent Director · since 2020
Catherine Larue
Independent Director · since 2017
Independent Director · since 2017
Jean-Francois Tine
Independent Director · since 2021
Headquarters & legal address
885 AVENUE EUGENE AVINEE
PARC EURASANTE
LOOS 59120
FR
PARC EURASANTE
LOOS 59120
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||